相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Cynthia X. Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis
Jiaqiang Zhang et al.
BREAST (2020)
Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy
Szu-Yuan Wu et al.
EUROPEAN JOURNAL OF CANCER (2019)
Treatment of advanced nasopharyngeal cancer using low-or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study
Tsung-Ming Chen et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer - The POETIC* Trial (CRUK/07/015)
John F. R. Robertson et al.
CANCER RESEARCH (2018)
Outcomes for Cervical Cancer Patients Treated With Radiation in High-Volume and Low-Volume Hospitals
Shih-Min Lin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: Chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy
Yen-Kuang Lin et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment
Yu-Chun Yen et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Yen-Kuang Lin et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Treatment outcomes for unresectable intrahepatic cholangiocarcinoma: Nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric
Wei-Wen Chang et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
Katsuhiko Nakatsukasa et al.
BREAST CANCER (2017)
Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma
Chia-Lun Chang et al.
RADIOTHERAPY AND ONCOLOGY (2017)
How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study
Anita Mamtani et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Curative-Intent Aggressive Treatment Improves Survival in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma and High Comorbidity Index
Jin-Hua Chen et al.
MEDICINE (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database
Brigid K. Killelea et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)
A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer
Fatemeh Bahreini et al.
BREAST CANCER (2015)
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C. Palmieri et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer
Xiaosong Chen et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
E. Alba et al.
ANNALS OF ONCOLOGY (2012)
Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!
Daniel F. Hayes
JOURNAL OF CLINICAL ONCOLOGY (2012)
Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer
Anne F. Schott et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer
Rebecca J. McClaine et al.
HPB (2010)
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy
Bhumsuk Keam et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Increase in response rate by prolonged treatment with neoadjuvant letrozole
J. Michael Dixon et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease
Julie R. Gralow et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
R. Torrisi et al.
BRITISH JOURNAL OF CANCER (2007)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study
TRJ Evans et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
An electronic application for rapidly calculating Charlson comorbidity score
WH Hall et al.
BMC CANCER (2004)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
